OCGN (Ocugen, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by OCGN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-17 | Treerita Essalima Johnson-Greene | Chief Financial Officer | Buy | — | — |
| 2026-06-15 | Kirsten Castillo | Director | A | — | — |
| 2026-06-15 | Satishchandran Chandrasekhar | Director | A | — | — |
| 2026-06-15 | Blaise Coleman | Director | A | — | — |
| 2026-06-15 | Junge Zhang | Director | A | — | — |
| 2026-06-15 | Uday Kompella | Director | A | — | — |
| 2026-04-02 | Junge Zhang | Director | M | — | — |
| 2026-01-06 | Ramesh Ramachandran | Chief Accounting Officer | A | — | — |
| 2026-01-06 | Shankar Musunuri | Chief Executive Officer | A | — | — |
| 2025-06-09 | Kirsten Castillo | Director | A | — | — |
| 2025-06-09 | Uday Kompella | Director | A | — | — |
| 2025-06-09 | Junge Zhang | Director | A | — | — |
| 2025-06-09 | Satishchandran Chandrasekhar | Director | A | — | — |
| 2025-06-09 | Blaise Coleman | Director | A | — | — |
| 2025-01-06 | Huma Qamar | Chief Medical Officer | A | — | — |
| 2025-01-06 | Ramesh Ramachandran | Chief Accounting Officer | A | — | — |
| 2025-01-06 | Arun Upadhyay | See Remarks | F | — | — |
| 2025-01-06 | Shankar Musunuri | Chief Executive Officer | F | — | — |
| 2024-12-02 | Prabhavathi Fernandes | Director | Buy | — | — |
| 2024-11-26 | Kirsten Castillo | Director | Buy | — | — |
| 2024-09-26 | Arun Upadhyay | See Remarks | F | — | — |
| 2024-07-02 | Junge Zhang | Director | A | — | — |
| 2024-07-02 | Arun Upadhyay | See Remarks | F | — | — |
| 2024-07-02 | MARNA C WHITTINGTON | Director | A | — | — |
| 2024-07-02 | Kirsten Castillo | Director | A | — | — |
| 2024-07-02 | Prabhavathi Fernandes | Director | A | — | — |
| 2024-07-02 | Uday Kompella | Director | A | — | — |
| 2024-04-17 | Huma Qamar | Chief Medical Officer | A | — | — |
| 2024-01-05 | Shankar Musunuri | Chief Executive Officer | F | — | — |
| 2024-01-05 | Arun Upadhyay | See Remarks | F | — | — |
| 2024-01-04 | Arun Upadhyay | See Remarks | A | — | — |
| 2024-01-04 | Shankar Musunuri | Chief Executive Officer | A | — | — |
| 2023-09-19 | Arun Upadhyay | See Remarks | F | — | — |
| 2023-06-20 | Arun Upadhyay | Chief Scientific Officer | F | — | — |
| 2023-06-16 | Junge Zhang | Director | Buy | — | — |
| 2023-06-09 | Kirsten Castillo | Director | A | — | — |
| 2023-06-09 | Junge Zhang | Director | A | — | — |
| 2023-06-09 | MARNA C WHITTINGTON | Director | A | — | — |
| 2023-06-09 | Uday Kompella | Director | A | — | — |
| 2023-06-09 | Prabhavathi Fernandes | Director | A | — | — |
| 2023-06-09 | Ramesh Kumar | Director | A | — | — |
| 2023-02-17 | Jessica Crespo | CAO/SVP, Finance | F | — | — |
| 2023-02-17 | Shankar Musunuri | Chief Executive Officer | MIXED | — | — |
| 2023-02-17 | Arun Upadhyay | Chief Scientific Officer | F | — | — |
| 2023-01-19 | Shankar Musunuri | Chief Executive Officer | MIXED | — | — |
| 2023-01-05 | Jessica Crespo | CAO/SVP, Finance | A | — | — |
| 2023-01-05 | Shankar Musunuri | Chief Executive Officer | A | — | — |
| 2023-01-05 | Arun Upadhyay | Chief Scientific Officer | A | — | — |
| 2022-12-20 | Shankar Musunuri | Chief Executive Officer | MIXED | — | — |
| 2022-10-14 | Shankar Musunuri | Chief Executive Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 6,101,223 | — |
| — | Director | 2,436,498 | — |
| — | Director | 705,090 | — |
| — | Chief Financial Officer | 521,350 | — |
| — | See Remarks | 306,197 | — |
| — | Chief Accounting Officer | 209,100 | — |
| — | CAO/SVP, Finance | 161,478 | — |
| — | Chief Financial Officer | 161,125 | — |
| — | Director | 75,000 | — |
| — | Director | 72,695 | — |
| — | Director | 10,000 | — |
| — | Senior Vice President | 4,900 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OCGN quote page; the site-wide leaderboard is on the insider transactions hub.